201 related articles for article (PubMed ID: 6212686)
1. A case of Di George syndrome treated with thymopoietin pentapeptide (TP-5) demonstrating an adherent suppressor cell of lymphocyte function.
Joffe MI; Sochett E; Pettifor JM; Rabson AR
J Clin Lab Immunol; 1982 May; 8(1):69-73. PubMed ID: 6212686
[TBL] [Abstract][Full Text] [Related]
2. Improvement of natural killer activity and of T cells after thymopoietin pentapeptide therapy in a patient with severe combined immunodeficiency.
Fiorilli M; Sirianni MC; Pandolfi F; Quinti I; Tosti U; Aiuti F; Goldstein G
Clin Exp Immunol; 1981 Aug; 45(2):344-51. PubMed ID: 7032772
[TBL] [Abstract][Full Text] [Related]
3. Thymopentin (TP-5) in the treatment of the postburn and postoperative immunodeficiency syndrome.
Hamilton G; Zöch G; Rath T; Meissl G
Prog Clin Biol Res; 1989; 308():995-9. PubMed ID: 2528748
[No Abstract] [Full Text] [Related]
4. Therapy with thymopoietin pentapeptide (TP-5) in 26 patients with primary immunodeficiencies.
Aiuti F; Businco L; Fiorilli M; Galli E; Quinti I; Le Moli S; Seminara R; Goldstein G
Birth Defects Orig Artic Ser; 1983; 19(3):267-72. PubMed ID: 6360238
[No Abstract] [Full Text] [Related]
5. Response to thymopoietin pentapeptide in patient with DiGeorge syndrome.
Aiuti F; Businco L; Rossi P; Quinti I
Lancet; 1980 Jan; 1(8159):91. PubMed ID: 6101433
[No Abstract] [Full Text] [Related]
6. Suppressor cell phenotype deficiency and its restoration by thymopoietin pentapeptide in atopic dermatitis.
Kang K; Strannegård O; Strannegård IL; Cooper K; Hanifin JM
Monogr Allergy; 1983; 18():181-5. PubMed ID: 6227816
[No Abstract] [Full Text] [Related]
7. Thymopoietin pentapeptide treatment of primary immunodeficiencies.
Aiuti F; Businco L; Fiorilli M; Galli E; Quinti I; Rossi P; Seminara R; Goldstein G
Lancet; 1983 Mar; 1(8324):551-4. PubMed ID: 6131256
[TBL] [Abstract][Full Text] [Related]
8. Abrogation of in vitro suppressor cell activity in adult common variable hypogammaglobulinemia after TP5 treatment.
Williams RC; Montano JD; Bankhurst AD
J Lab Clin Med; 1983 Jan; 101(1):152-60. PubMed ID: 6217268
[TBL] [Abstract][Full Text] [Related]
9. Normalization of the CD4/CD8 lymphocyte ratio and increased B lymphocytes in long standing diabetic patients following therapy with thymopentin.
Pozzilli P; Visalli N; Cavallo MG; Beales P; Negri M; Ghirlanda G; Papa V; Andreani D
Diabetes Res; 1987 Oct; 6(2):51-6. PubMed ID: 2962799
[TBL] [Abstract][Full Text] [Related]
10. Effect of synthetic thymic hormone (TP5) in children with T-cell immunodeficiencies.
Levinsky RJ; Davies EG; Goldstein G
Birth Defects Orig Artic Ser; 1983; 19(3):273-6. PubMed ID: 6360239
[No Abstract] [Full Text] [Related]
11. Effects of thymopoietin pentapeptide (TP-5) on in vitro and in vivo IgE production by atopic dermatitis cell subsets.
Cooper KD; Kang K; Hanifin JM
Diagn Immunol; 1983; 1(3):211-5. PubMed ID: 6388971
[TBL] [Abstract][Full Text] [Related]
12. The effect of thymopentin treatment on the relapse rate in frequently relapsing herpes simplex virus infections.
Haneke E; Bolla K; Degreef H; Djawari D; Demaubeuge J; Molin L; Panconesi E; Schöpf E; Stengel R; Stingl G
Int J Clin Pharmacol Res; 1984; 4(6):439-43. PubMed ID: 6085327
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human T lymphocyte E rosette formation by neutrophils and hydrogen peroxide. Differential sensitivity between helper and suppressor T lymphocytes.
Staite ND; Messner RP; Zoschke DC
J Immunol; 1987 Oct; 139(7):2424-30. PubMed ID: 2958549
[TBL] [Abstract][Full Text] [Related]
14. Results in two infants with the DiGeorge syndrome--effects of long-term TP5.
Businco L; Rubaltelli FF; Paganelli R; Galli E; Ensoli B; Betti P; Aiuti F
Clin Immunol Immunopathol; 1986 May; 39(2):222-30. PubMed ID: 3084141
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of monoclonal antibodies in the diagnosis and monitoring of patients with primary immunodeficiencies: combined experience in three clinical immunology centers.
Aiuti F; Quinti I; Seminara R; Sirianni MC; Vierucci A; Abo T; Cooper MD
Diagn Immunol; 1983; 1(3):188-94. PubMed ID: 6388970
[TBL] [Abstract][Full Text] [Related]
16. Functional heterogeneities among concanavalin A-activated OKT4+ and OKT8+ cells by using autologous erythrocyte rosette technique.
Takada S; Ueda Y; Murakawa Y; Suzuki N; Sakane T
J Clin Invest; 1983 Dec; 72(6):2060-71. PubMed ID: 6227636
[TBL] [Abstract][Full Text] [Related]
17. Lymphocyte subpopulations in primary immunodeficiency disorders.
Davies EG; Levinsky RJ; Butler M; Thomas RM; Linch DC
Arch Dis Child; 1983 May; 58(5):346-51. PubMed ID: 6344803
[TBL] [Abstract][Full Text] [Related]
18. Flow cytometric analysis of lymphocyte subpopulations after thermal injury in human beings.
Antonacci AC; Reaves LE; Calvano SE; Amand R; De Riesthal HF; Shires GT
Surg Gynecol Obstet; 1984 Jul; 159(1):1-8. PubMed ID: 6234669
[TBL] [Abstract][Full Text] [Related]
19. Restoration of the impaired lymphocyte stimulation in old people by thymopoietin pentapeptide.
Verhaegen H; De Cock W; De Cree J; Goldstein G
J Clin Lab Immunol; 1981 Sep; 6(2):103-5. PubMed ID: 7026790
[TBL] [Abstract][Full Text] [Related]
20. Thymopoietin pentapeptide (TP-5) improves clinical parameters and lymphocyte subpopulations in atopic dermatitis.
Kang K; Cooper KD; Hanifin JM
J Am Acad Dermatol; 1983 Mar; 8(3):372-7. PubMed ID: 6339571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
